Home › Prostate Cancer › Minnesota › Minneapolis
Prostate Cancer clinical trials in Minneapolis, MN
22 studies for Prostate Cancer are looking for participants at sites in and around Minneapolis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
RecruitingPhase 3
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Health Partners Inc, Minneapolis
- and 1 more
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
- Hennepin County Medical Center, Minneapolis
The Vanguard Study: Testing a New Way to Screen for Cancer
RecruitingHealthy volunteers welcome
- Minneapolis VA Medical Center, Minneapolis
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi away
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
RecruitingPhase 1
- University Of Minnesota, Minneapolis
Evaluating Prostate Cancer Patient Natural Killer Cell Function Across Racial Background and Addressing Functional Disparities With Trispecific Killer Engagers
RecruitingObservational study
- University of Minnesota/Masonic Cancer Center, Minneapolis
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
RecruitingPhase 3
- HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0032), Saint Louis Park · 5 mi away
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RecruitingPhase 1
- University of Minnesota Medical Center, Minneapolis
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 2
- Health Partners Frauenshuh Cancer Center, Saint Louis Park · 5 mi away
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
RecruitingPhase 3
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi away
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
RecruitingPhase 3
- HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0072), Saint Louis Park · 5 mi away
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
RecruitingPhase 3
- Minnesota Oncology Hematology PA, Minneapolis
- University of Minnesota Medical Center Fairview, Minneapolis
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
RecruitingPhase 1/2
- Research Site, Minneapolis
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
RecruitingPhase 3
- Hennepin County Medical Center, Minneapolis
- Health Partners Inc, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi away
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- M Health Fairview University of Minnesota Medical Center, Minneapolis
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
RecruitingPhase 1
- M Health Fairview Clinics and Surgery Center, Minneapolis
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
RecruitingPhase 2
- Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
RecruitingPhase 2
- Masonic Cancer Center, Minneapolis
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
RecruitingPhase 1
- Minnesota Oncology Hematology, Minneapolis
Axelopran for Advanced Cancer in Patients Receiving Opioids
RecruitingPhase 2
- HealthPartners Frauenshuh Cancer Research Center, Saint Louis Park · 5 mi away
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
RecruitingPhase 3
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Health Partners Inc, Minneapolis
- and 1 more
Vitamin D for Prostate Endocrine Therapy
RecruitingPhase 3
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi away
About Prostate Cancer
Prostate cancer is one of the most common types of cancer among American men. The risk goes up as men age. Learn about symptoms, tests, and treatment.
More about Prostate Cancer on MedlinePlus
Prostate Cancer trials in other cities
- New York City, NY101 studies
- Houston, TX73 studies
- Los Angeles, CA64 studies
- Boston, MA56 studies
- Seattle, WA45 studies
- St. Louis, MO45 studies
- Chicago, IL45 studies
- Baltimore, MD45 studies
- San Francisco, CA44 studies
- Philadelphia, PA41 studies
- Nashville, TN40 studies
- Washington, DC39 studies
Other studies in Minneapolis
- Non-Small Cell Lung Cancer29 studies
- Breast Cancer23 studies
- Ovarian Cancer23 studies
- Heart Failure22 studies
- Cancer (all types)21 studies
- Endometrial Cancer20 studies
- Colorectal Cancer20 studies
- Lung Cancer20 studies
- Acute Myeloid Leukemia19 studies
- Parkinson's Disease17 studies
- Coronary Artery Disease15 studies
- Cardiovascular Disease15 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.